A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer

INTRODUCTION: Clinical evidence suggests that first-line immune checkpoint inhibitor (ICI) combination therapies can improve survival in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC). However, the optimal strategy remains unknown without a systematic comparison of their...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Taihang, Zhao, Mingye, Liang, Leyi, Tang, Wenxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645411/
https://www.ncbi.nlm.nih.gov/pubmed/36389713
http://dx.doi.org/10.3389/fimmu.2022.948597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645411/
https://www.ncbi.nlm.nih.gov/pubmed/36389713
http://dx.doi.org/10.3389/fimmu.2022.948597

Ejemplares similares